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Abstract
2While the pathogenesis of Parkinson’s disease is not fully understood, there is increasing
evidence that inflammatory responses in the brain are implicated in both disease initiation and
progression. The inflammatory process in Parkinson’s disease is however not limited to the
brain but also involves the gastrointestinal tract. High amounts of cytokines and inflammatory
markers are found in the colon of Parkinson’s disease patients and there is now strong
epidemiological and genetical evidence linking Parkinson’s disease to inflammatory bowel
diseases. Recent findings obtained in both experimental inflammatory bowel diseases and
Parkinson’s disease further support a bidirectional link between gastrointestinal inflammation
and brain neurodegeneration. Altogether these observations suggest a role for gastrointestinal
inflammation in the initiation and progression of Parkinson’s disease.
Keywords: Parkinson’s disease; inflammatory bowel disease; Crohn’s disease; ulcerative
colitis; enteric nervous system; LRRK2.
3An accumulating body of literature has emerged over recent years to show that Parkinson’s
disease (PD) is not only disorder of the brain but also of the gut-brain axis (reviewed in [1]).
Gastrointestinal (GI) symptoms occur in almost every PD patient at some point [2] and post
mortem studies have consistently shown that alpha-synuclein aggregates are found in the enteric
nervous system (ENS) in almost all cases [3–5]. Recent reports have shown that, aside from
enteric neuropathology and GI dysfunction, PD patients also exhibit some degree of GI
inflammation. The possible link between GI inflammation and PD is further reinforced by
observations showing that PD and inflammatory bowel disease (IBD) are genetically and
epidemiologically linked. In the first part of this review, we summarize the current knowledge
on GI inflammation in PD while the second part is dedicated to the possible role of GI
inflammation in the development of the disease.
PD and IBD are genetically linked
In 2007, Bialecka et al. published the first paper on a possible genetic link between IBD and PD
[6]. They focused on the CARD15/NOD2 (caspase recruitment domain-containing protein
15/Nucleotide-binding oligomerization domain-containing protein 2), which is associated with
Crohn’s disease (CD) and encodes for intracellular signalling molecules that recognize bacterial
components and mediate the activation of nuclear factor-kappa B (NF-𐀀B) [7]. They found a
higher frequency of 3 CARD15/NOD2 gene variants previously associated with CD in a group
of 308 sporadic PD patients when compared to 220 controls [6]. The Leucine-rich repeat kinase
2 (LRRK2) gene, which has emerged as the gene most commonly associated with both familial
and sporadic PD, has been subsequently identified by genome-wide association studies as a
major susceptibility gene for CD [8]. A recent exome-sequencing study performed in Ashkenazi
Jews by identifying functional gene variants in LRRK2 that conferred either increased risk or
protection from both CD and PD, ties even closer these two disorders [9].
PD and IBD are epidemiologically linked
In 1995, based on a short case series, Bihari and Lees suggested that there might be an
unrecognized association between PD and ulcerative colitis (UC) [10]. Nothing has been
published on this subject for the next 20 years but the genetic overlap between PD and CD
relaunched the debate. While a small monocentric retrospective study did not observe any
increased occurrence of CD in PD patients [11], four large nationwide surveys showed that IBD
patients had an increased risk of subsequent PD compared to controls [12–15] ( table 1). After
combining the data of these four studies, a recent meta-analysis showed that the overall risk of
4PD in IBD was significantly higher than controls (relative risk 1.41, 95% confidence interval:
1.19-1.66), with a 28% and 30% increased risk of PD for CD and UC, respectively [16]. Two
studies (American and Swedish) reported an increased hazard ratio in both CD and UC groups
[13, 15] (table 1). The Danish study demonstrated that the risk of PD was significantly higher
among patients with UC but not with CD, while the Taiwanese one showed the opposite (Table
1). Interestingly, in the American cohort, an almost 80% reduction in the incidence rate of PD
was observed among IBD patients who were exposed to anti-TNF therapy compared with those
who were not exposed, suggesting that systemic inflammation is involved in the pathogenesis of
both diseases [13].
Appendectomy and PD
So far, 6 studies investigated the possible association between appendectomy and PD [17–22],
with the hypothesis that appendectomy would be associated with a reduction in the risk of
subsequent PD. This assumption primarily relied on the observation that the vermiform
appendix, which is innervated by the vagus nerve [23], contains high amounts of alpha-
synuclein [24]. Another plausible hypothesis is that appendectomy might indirectly reduce the
incidence of PD by decreasing the risk of IBD [25]. Among these 6 studies, two observational
[18, 20] and 3 cohorts’ studies found no association between appendectomy and PD risk [17, 19,
21] (Table 2). Much has been written about a recent article, which, by contrast to all other
existing studies found that the risk to develop PD was significantly lower (almost 20%) in
subjects with appendectomy compared to those without appendectomy: PD incidence was 1.60
per 100,000 person-years (95% confidence interval, 1.46-1-75) versus 1.98 (95% confidence
interval, 1.87-2.10), respectively. They also found that the healthy human appendix contains
pathological post-translationally modified forms of alpha-synuclein, suggesting that the
appendix may be a preferential site of origin for PD [22]. These are novel and intriguing
findings, but further studies are critically needed to determine if the observed post-translational
modifications of alpha-synuclein are specific to the appendix or also observed in adjacent GI
tract segments such as ileum and colon.
PD patients exhibit GI tract inflammation
The genetic link between PD and IBD along with the role of CNS inflammation in the
development of PD, prompted us to search for the presence of GI tract inflammation in PD
patients. In a seminal study, we analyzed the expression levels of the main pro-inflammatory
cytokines (tumor necrosis factor-𐀀, interferon-𐀀, interleukin-6 and interleukin-1𐀀) in colonic
5biopsies from 19 PD patients and 14 age-matched healthy controls. We found that the mRNA
expression levels of all pro-inflammatory cytokines were significantly elevated in the ascending
and descending colon of PD patients when compared to controls [26] (Figure 1). By contrast, no
changes were observed when colonic biopsies from patients with multiple system atrophy and
progressive supranuclear palsy were analyzed, suggesting that the observed changes in
cytokines expression are specific to PD (Figure 1). Using a similar approach, we also showed
that the expression of the pro-inflammatory enzyme cyclooxygenase-2 (COX-2) was also
increased in PD [27]. We were nevertheless struck by the heterogeneity of amounts of cytokines
among PD patients, as some showed levels similar to control subjects while others had up to a 6-
fold upregulation. Correlation analyses showed that all pro-inflammatory cytokines were up-
regulated within the same patients, suggesting that not all but only a subset of PD patients had an
“enteric pro-inflammatory profile” [26]. In addition, the levels of all pro-inflammatory
cytokines were negatively correlated with disease duration but not correlation was observed
with GI symptoms, disease severity or cumulative lifetime dose of L-DOPA [26]. Our results
were further confirmed by another research group that used a microarray approach to analyze a
panel of genes involved in inflammatory pathways in sigmoid biopsies from 6 PD and 4 controls
[28].
The analysis of GI inflammation based on stool specimens has already been successfully
used in large cohorts of IBD patients [29]. This logically led Houser et al. to conduct an
extensive analysis of immune- and inflammatory-related proteins in the stool of 156 individuals
with PD and 110 controls using multiplex immunoassay [30]. They found elevated levels of
interleukin-1𐀀, 1𐀀and C-reactive protein in the stool of PD patients. Although not significant,
the levels of some upregulated factors tended to be inversely correlated with age and disease
duration [30]. Using a more focused approach, Schwiertz et al. found that calprotectin, a fecal
marker of intestinal inflammation was also significantly increased in the feces of PD patients
when compared to controls [31].
Altogether, these studies provide converging evidence that classic inflammatory
processes are overly active in GI tract in PD patients and also suggest and that GI inflammation
is more likely to occur in patients with a short disease duration. These observations are in
keeping with the findings obtained in the CNS, which showed that microglia activation occurs
early in the disease process.
Gut inflammation in rodents is associated with central dopaminergic neurodegeneration
and vice versa
6The most widely used mouse model of colitis in rodents employs dextran sodium sulfate (DSS),
a chemical colitogen with anticoagulant properties, to induce disease. DSS is a water-soluble,
negatively charged sulfated polysaccharide with a highly variable molecular weight ranging
from 5 to 1400 kDa. Acute, chronic and relapsing models of intestinal inflammation can be
achieved by modifying the concentration of DSS as well as the frequency of administration and
clinical signs of disease appear as soon as one day post treatment, with an increased expression
of the main proinflammatory cytokines [32]. Using an acute regimen, Villaran and colleagues
were the first to show that rats with DSS-induced colitis were more sensitive to a model of
dopaminergic neurodegeneration based on the injection of lipopolysaccharide in the substantia
nigra [33]. More recently, another Spanish group observed that chronic treatment with DSS in
mice was associated with dopaminergic neuronal death along with an increased expression of
interleukin-1𐀀in the susbtantia nigra [34]. An Italian group from Pisa, by hypothesizing that
central dopaminergic degeneration might induce gut inflammation, turned the problem on its
head. To this end, they analyzed the modifications of the GI tract in the 6-hydroxydopamine (6-
OHDA) model of experimental parkinsonism. This neurotoxin, which does not cross the
blood–brain barrier, is classically injected into the substantia nigra and/or in the medial
forebrain bundle and produces a massive lesion of nigral dopaminergic cell bodies [35]. The
induction of central nigrostriatal dopaminergic degeneration by 6-OHDA was followed after 4
or 8 weeks by bowel inflammation associated with increase in pro-inflammatory cytokine levels
(tumor necrosis factor-𐀀 and interleukin-1𐀀𐀀𐀀and activation of enteric glia [36]. Because a
previous study showed that 6-OHDA rats had a decrease in cholinergic neurons of the dorsal
motor nucleus of the vagus [37], it is reasonable to hypothesize that the central dopaminergic
neurodegeneration triggered by 6-OHDA induces GI tract inflammation through an impairment
of the dorsal motor nucleus of the vagus/vagus nerve anti-inflammatory pathway (Figure 2).
HowGI inflammationmay influence the development of PD?
In light of the increasing evidence showing that PD patients exhibit gut inflammation, a
relatively straightforward scenario for PD pathogenesis has been proposed [38, 39]. In such a
model, an unknown pathogen triggers intestinal inflammation, which in turn induces the
expression and aggregation of alpha-synuclein in submucosal neurons whose terminal axons are
only micrometers away from the gut lumen. The pathological process would then further spread
to the brain via the vagal preganglionic innervation of the gut, as this has been already
demonstrated for neural tracers [40] (Figure 2). What are the arguments for and against this
scenario? Regarding the role of the vagus nerve, two Scandinavian studies showed that full
7truncal vagotomy was associated with a decreased risk for subsequent PD, suggesting that vagal
innervation may be involved in the development of PD [41, 42]. These cohorts’ findings are
supported by the observation that several changes observed in the brain of DSS-treated mice,
such as decrease in TH expression and nigral neuronal loss were partly prevented by vagotomy
[34]. When it comes to inflammation-induced spreading of alpha-synuclein from the gut to the
brain, things are a bit more complicated. In an attempt to reinforce the possible association
between PD and IBD, we analyzed the expression levels and the post translational
modifications of alpha-synuclein in IBD. Although we identified an elevated amount of alpha-
synuclein in colonic samples from patients with CD, we were unable to find any pathological
changes such as phosphorylation and aggregation known to be associated with PD [43]. In
addition, two independent studies performed in both acute and chronic DSS-treated mice found
that intestinal inflammation was not associated with any increase in alpha-synuclein expression
and phosphorylation [34, 44] and we recently showed that alpha-synuclein in enteric neurons
was transcriptionally downregulated by acute inflammation via a p38 signaling pathway [44].
Although far from being definitive, these findings cast a doubt on the direct implication of
enteric alpha-synuclein in the effects of GI inflammation in PD. An alternative scenario, which
does not involve alpha-synuclein, suggests that the increased intestinal permeability and
systemic inflammation is sufficient to lead to blood-brain barrier disruption, brain
inflammation, and ultimately alteration in brain dopaminergic function [45](Figure 2b). Apart
from these two “bottom-up” hypotheses, a “top-down” hypothesis in which GI inflammation
results from a compromised vagal pathway is also plausible [46](Figure 2c).
Why not all IBD patients develop PD?
All the above arguments support a role for GI inflammation in the pathogenesis of PD. However
the associations between IBD and PD are small in magnitude and one may wonder why only a
small subset and not the vast majority of IBD patients will subsequently develop PD and vice
versa (for example, the difference observed in the Swedish cohort [15] between IBD and
controls corresponds to 1 extra case of PD for every 10,000 IBD patients followed for a year).
These findings remind us that the pathogenesis of PD is far from being understood and the
movement disorders research field is now questioning the accuracy of considering PD as a
single entity [47]. In a recent opinion paper, Brundin’s group proposes that factors contributing
to neurodegeneration in PD could be classified into three categories: triggers, facilitators, and
aggravators [48]. They first acknowledge that with the exception of relatively rare genetic forms
of PD and MPTP intoxication, triggers of PD remain largely unknown. Regarding facilitators,
8which are defined as factors that potentiate the effects of triggers on the nervous system or
spread the pathology to more central parts of the nervous system, the list of potential candidates
is a bit longer, including among others systemic inflammation, mitochondrial dysfunction and
clearance of neurotoxic proteins [49]. One might therefore posit that GI inflammation in PD is
one more facilitator that would explain a small part of the etiologic puzzle of PD.
Conclusions and perspectives, what are the next steps?
It’s only in the past few years that neurologists and neuroscientists started to get interested in GI
inflammation in PD and, although interesting, the existing research on this topic is still at a
rather preliminary stage. The first results obtained in PD patients suggest that GI inflammation
is inversely correlated to disease duration [26, 30] but these findings need to be confirmed in
larger sample size studies that will enroll drug naïve patients as well as subjects with isolated
REM sleep behavior disorder with a longitudinal evaluation of their gut inflammatory status. In
addition to the utilization of cutting-edge technology for a large detection of inflammatory
markers, it will be also critical to comprehensively assess the motor and nonmotor features in
each patient in order to determine if PD patients with high levels of enteric inflammation have a
more severe disease course and progression or not. The role of LRRK2 in linking GI
inflammation, immunity and PD is another avenue to be explored. A recent study showed that
transgenic mice overexpressing LRRK2 are more sensitive to DSS-induced colitis and that
normalization of LRRK2 activation blocks the release of TNF-𐀀by cultured dendritic cells from
CD patients [50]. In order to explore the role of LRRK2 and gut inflammation, it might be
relevant to study neurodegeneration and alpha-synuclein pathology in the ENS and the CNS of
these mice and to perform additional experiments, including LRRK2 expression and
phosphorylation in GI samples of PD patients. Finally, the recent PET studies by Per
Borghammer’s group, showing that it is possible to evaluate the parasympathetic denervation of
the GI tract in living PD patients [46] also open new opportunities for a better understanding of
the role of GI inflammation in the development of the disease. Combining this approach to a
comprehensive analysis of inflammation marker in GI samples or feces would allow us to
correlate the degree of vagal denervation to the inflammatory status in the GI tract and thus to
confirm or not that GI inflammation might be a key starting event in PD.
9Country Period IBD cases HR CD/C HR UC/C
Denmark [14] 1977-2014 76,477 1.12 (0.89–1.40) 1.35* (1.20-1.52)
Sweden [15] 2002-2014 39,652 1.6* (1.1-2.3) 1.4* (1.2-1.8)
US [13] 2000-2016 144,018 1.26* (1.03-1.53) 1.31* (1.14-1.51)
Taiwan [12] 2000-2011 8,373 1.4* (1.11–1.77) 0.94 (0.49–1.84)
Table 1. Existing epidemiological cohort studies on the association between IBD and PD.
HR: hazard ratio; the numbers in bracket are the 95% confidence interval; * is for statistically
significant.
Country Years of app. App. cases HR app./C
Denmark [21] 1980-2010 265,758 1.14 (1.03–1.27)
Canada [17] 1997-2007 42,999 1.004 (0.74-1.36)
USA [19] 1976-1992 442,700 1.08 (0.94-1.23)
USA [22] 1964-2015 551,647 1.60* (1.46-1-75) vs 1.98 (1.87-2.10)$
Table 2. Existing epidemiological cohort studies on the association between appendectomy
and PD. HR: hazard ratio; the numbers in bracket are the 95% confidence interval; * is for
statistically significant. App. is for appendectomy. $ shows PD incidence per 100,000 person-
years in subjects with appendectomy compared to those without appendectomy, respectively.
Legends to figures
Figure 1: Colonic expression of pro-inflammatory cytokines in PD and atypical
parkisonism. The mRNA expression levels of TNF-𐀀(A), IFN𐀀(B), IL-6 (C) and IL-1𐀀(D) are
significantly increased in colonic biopsies (descending colon) from PD patients (n=29) as
compared to control subjects (n=29) (p=0.0008, p=0.004, p=0.003 and p=0.03, respectively).
The mRNA expression levels of TNF-𐀀 (A), IFN𐀀 (B), IL-6 (C) and IL-1𐀀 (D) are not
significantly different between progressive supranuclear palsy (PSP,n=8) and control subjects
(n=29) (p=0.74, p=0.35, p=0.23, p=0.28, respectively) and between multiple system atrophy
(MSA, n=6) and controls (n=29) (p=0.30, p=0.12, p=0.08 and p=0.14, respectively). Horizontal
bars represent the mean. Differences between mRNA expression levels of patients and controls
were analyzed by unpaired two-tailed Mann-Whitney test. For all statistical tests p<0.05 was
deemed significant. *p<0.05, **p<0.01 and ***p<0.001 as compared to controls.
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Figure 2: Proposed hypotheses linking GI tract inflammation and PD. (A)GI inflammation
might set off alpha-synuclein expression and aggregation in submucosal neurons and alpha-
synuclein pathology would then subsequently spread to the brain via the vagus nerve. (B) The
effects of GI inflammation on the brain could be mediated through systemic inflammation. (C)
Finally, it might be also hypothesized that the dopaminergic denervation in the CNS induces GI
tract inflammation through an impairment of the dorsal motor nucleus of the vagus/vagus nerve
anti-inflammatory pathway. This figure was created using ServierMedical Art templates, which
are licensed under a Creative Commons Attribution 3.0 Unported License.
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